The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose escalation trial of ex-vivo expanded allogeneic cord blood–derived natural killer cell immunotherapy for pediatric solid tumor malignancies.
 
Sajad Khazal
No Relationships to Disclose
 
Jonathan Benjamin Gill
Consulting or Advisory Role - Acceleron Pharma (I); Acceleron Pharma (I); Celgene (I); Grail (I); ImmunityBio (I); Legend Biotech (I); MEI Pharma (I); MEI Pharma (I)
 
Jessica Foglesong
No Relationships to Disclose
 
Sireesha Yedururi
No Relationships to Disclose
 
Ajaykumar Morani
No Relationships to Disclose
 
Dawen Sui
No Relationships to Disclose
 
Roland L. Bassett
No Relationships to Disclose
 
Suzanne Gettys
No Relationships to Disclose
 
Priti Tewari
No Relationships to Disclose
 
Kris Mahadeo
No Relationships to Disclose
 
Richard Greg Gorlick
Research Funding - Eisai (Inst)
 
Elizabeth J. Shpall
Honoraria - Bayer
Consulting or Advisory Role - Adaptimmune; AXIO Research; Celaid Therapeutics; Fibrobiologics; Navan; NY Blood Center
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics; Takeda
Travel, Accommodations, Expenses - Magenta Therapeutics; Novartis
 
Katy Rezvani
Consulting or Advisory Role - Avenge Bio; Bayer; Caribou Biosciences; GEMoaB; GlaxoSmithKline; NAVAN Technologies; Virogen
Research Funding - Affimed Therapeutics; Pharmacyclics; Takeda
Patents, Royalties, Other Intellectual Property - License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy.; License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy. (Inst); License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy (Inst); Patent on generation of BKV CTLs for the treatment of HC or PML; Patent on generation of CAR NK cells
 
Najat C. Daw
Consulting or Advisory Role - Bayer; Incyte; Plus Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Two Provisional Patents for radiotherapeutic microspheres were filed in 2019 and 2021 at University of Texas Health Science Center at San Antonio. (I)